Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2023-01-04 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Vivo Bio Tech Limited has informed the exchange that the Company has today allotted 27,000 Equity Shares under Vivo Bio Employees Stock Option Scheme, 2016 to the eligible employees of ....
Share Issue/Capital Change Classification · 95% confidence The document is a short notification letter addressed to the stock exchange regarding the allotment of equity shares under an Employee Stock Option Plan (ESOP). It mentions the increase in issued and subscribed share capital due to the allotment of shares. The document is brief (1093 characters) and serves as an announcement of a capital change rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data. Therefore, it fits the category of a Share Issue/Capital Change announcement.
2023-01-04 English
Vivo Bio Tech Limited has informed the exchange that, pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Company's Internal Code of Conduct to Regulate, Monitor and ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about the closure of the trading window in compliance with SEBI regulations related to insider trading. It mentions the period of closure around the announcement of the company's un-audited financial results for the quarter and nine months ended December 31, 2022. The document does not contain any financial data, detailed report, or analysis. It is an announcement related to regulatory compliance and trading restrictions, not a financial report or earnings release itself. Given the short length (1168 characters) and the nature of the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-31 English
Vivo Bio Tech Limited has informed the exchange that with reference to the Company''s letter dated December 12, 2022, the Board of Directors of the Company at their meeting held today, ....
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) reporting the outcome of a Board Meeting held on December 21, 2022. The content focuses on the approval for engagement/appointment of consultants for a proposed issuance of equity shares/warrants by preferential allotment. It references compliance with SEBI regulations and the Companies Act. The document is short (2180 characters) and serves as an official announcement of board decisions rather than a detailed report or financial statement. It does not contain financial data or detailed management discussion but is an announcement of board meeting outcomes related to capital raising activities. Therefore, it fits best under Capital/Financing Update (CAP).
2022-12-21 English
VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/12/2022 ,inter alia, to consider and approve 1. Proposal for issuance of ....
Board/Management Information Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about the date of an upcoming Board Meeting and the closure of the trading window. It mentions the agenda items such as a proposal for issuance of equity shares/warrants and convening an Extraordinary General Meeting or Postal Ballot for shareholder approval. The document is short (2282 characters) and serves as an announcement of a future event rather than a report or detailed filing. It does not contain financial data, audit information, or detailed management discussion. It is clearly an announcement related to board activities and regulatory compliance regarding insider trading and shareholder meetings. Therefore, the document fits best under the category of Board/Management Information (MANG).
2022-12-12 English
Vivo Bio Tech Limited has submitted with the exchange the copies of advertisement issued in newspapers on November 16, 2022, in 'Financial Express' in English Language and in 'Nava Telangana' ....
Regulatory Filings
2022-11-16 English
Vivo Bio Tech Limited has submitted with the exchange the Un-Audited Standalone & Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2022.
Regulatory Filings
2022-11-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.